ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer

Cetuximab is one of the most valuable targeted therapy monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC). However, the mechanisms affecting cetuximab resistance in CRC treatment remain unclear. Metabolism, especially fatty acid metabolism, has been reported to play an impo...

Full description

Bibliographic Details
Main Authors: Hong Hi-Ju, Shao Yanfei, Zhang Sen, Yang Guang, Jia Hongtao, Yang Xiao, Huang Ling, Li Shuchun, Aikemu Batuer, Zhang Luyang, Ma Junjun, Zang Lu, Sun Jing, Zheng Minhua
Format: Article
Language:English
Published: China Science Publishing & Media Ltd. 2022-09-01
Series:Acta Biochimica et Biophysica Sinica
Subjects:
colorectal cancer
cetuximab
targeted therapy
ACACB
comprehensive analysis
Online Access:https://www.sciengine.com/doi/10.3724/abbs.2022121

Internet

https://www.sciengine.com/doi/10.3724/abbs.2022121

Similar Items